Kongsuphol Patthara, Jia Huan, Cheng Hoi Lok, Gu Yue, Shunmuganathan Bhuvaneshwari D/O, Chen Ming Wei, Lim Sing Mei, Ng Say Yong, Tambyah Paul Ananth, Nasir Haziq, Gao Xiaohong, Tay Dousabel, Kim Seunghyeon, Gupta Rashi, Qian Xinlei, Kozma Mary M, Purushotorman Kiren, McBee Megan E, MacAry Paul A, Sikes Hadley D, Preiser Peter R
Antimicrobial Resistance Interdisciplinary Research Group (AMR-IRG), Singapore-MIT Alliance in Research and Technology (SMART), #03-10/11 Innovation Wing, 1 CREATE way, Singapore, 138602 Singapore.
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), 5 Science Drive 2, Blk MD4, Level 3, Singapore, 117545 Singapore.
Commun Med (Lond). 2021 Nov 11;1:46. doi: 10.1038/s43856-021-00045-9. eCollection 2021.
Neutralizing antibodies (NAbs) prevent pathogens from infecting host cells. Detection of SARS-CoV-2 NAbs is critical to evaluate herd immunity and monitor vaccine efficacy against SARS-CoV-2, the virus that causes COVID-19. All currently available NAb tests are lab-based and time-intensive.
We develop a 10 min cellulose pull-down test to detect NAbs against SARS-CoV-2 from human plasma. The test evaluates the ability of antibodies to disrupt ACE2 receptor-RBD complex formation. The simple, portable, and rapid testing process relies on two key technologies: (i) the vertical-flow paper-based assay format and (ii) the rapid interaction of cellulose binding domain to cellulose paper.
Here we show the construction of a cellulose-based vertical-flow test. The developed test gives above 80% sensitivity and specificity and up to 93% accuracy as compared to two current lab-based methods using COVID-19 convalescent plasma.
A rapid 10 min cellulose based test has been developed for detection of NAb against SARS-CoV-2. The test demonstrates comparable performance to the lab-based tests and can be used at Point-of-Care. Importantly, the approach used for this test can be easily extended to test RBD variants or to evaluate NAbs against other pathogens.
中和抗体（NAbs）可防止病原体感染宿主细胞。检测严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体对于评估群体免疫和监测针对导致2019冠状病毒病（COVID-19）的SARS-CoV-2疫苗的效力至关重要。目前所有可用的中和抗体检测都是基于实验室的，且耗时较长。
我们开发了一种10分钟的纤维素下拉试验，用于从人血浆中检测针对SARS-CoV-2的中和抗体。该试验评估抗体破坏血管紧张素转换酶2（ACE2）受体-受体结合域（RBD）复合物形成的能力。简单、便携且快速的检测过程依赖于两项关键技术：（i）基于垂直流纸的检测形式，以及（ii）纤维素结合域与纤维素纸的快速相互作用。
在此我们展示了一种基于纤维素的垂直流检测方法的构建。与目前使用COVID-19康复期血浆的两种基于实验室的方法相比，所开发的检测方法具有80%以上的灵敏度和特异性，以及高达93%的准确率。
已开发出一种快速的10分钟基于纤维素的检测方法，用于检测针对SARS-CoV-2的中和抗体。该检测方法与基于实验室的检测方法性能相当，可在即时检测点使用。重要的是，该检测方法所采用的方法可轻松扩展，以检测RBD变体或评估针对其他病原体的中和抗体。
